major impact
Healthcare
FDA Expands Semaglutide Approval for Chronic Kidney Disease
Food and Drug Administration
United States
Published Jun 20, 2025
Summary
The FDA expanded the approval of semaglutide (Ozempic) to include patients with type 2 diabetes and chronic kidney disease, making it the only GLP-1 receptor agonist approved to reduce cardiovascular risks and slow kidney disease progression simultaneously.
Key Changes
- Expanded indication for chronic kidney disease
- Dual cardiovascular and renal protection
- New standard of care for diabetic kidney disease
Affected Industries
Pharmaceuticals
Healthcare
Nephrology
Source
Key Dates
PublishedJun 20, 2025
Added to RegIntelJun 20, 2025
Related Regulations
SEC Launches Project Crypto Initiative for Digital Asset Framework
SEC · Jul 31, 2025
SEC Permits In-Kind Redemptions for Crypto Asset ETPs
SEC · Jul 29, 2025
SEC Issues Guidance on Crypto Asset Custody by Broker-Dealers
SEC · Dec 17, 2025
SEC Clarifies Liquid Staking Activities Not Securities
SEC · Aug 5, 2025
FDA Approves Suzetrigine (Journavx) - First New Acute Pain Drug in 20 Years
FDA · Jan 30, 2025